{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:50:45Z","timestamp":1776779445568,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the \"Tianshan Innovation Team Plan\" by the Science and Technology Department of Xinjiang Uygur Autonomous Region","award":["2022D14008"],"award-info":[{"award-number":["2022D14008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-73325-8","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T09:01:45Z","timestamp":1727514105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the prognostic value of T follicular helper cell levels in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"14","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"22","key":"73325_CR1","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood.2020005964","volume":"137","author":"E Kennedy","year":"2021","unstructured":"Kennedy, E. et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood 137 (22), 3064\u20133078 (2021).","journal-title":"Blood"},{"key":"73325_CR2","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps, T. J. et al. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Primers 3, 16096 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"73325_CR3","doi-asserted-by":"publisher","first-page":"e951","DOI":"10.1097\/HS9.0000000000000951","volume":"7","author":"PJ Hengeveld","year":"2023","unstructured":"Hengeveld, P. J. et al. High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL. Hemasphere 7 (10), e951 (2023).","journal-title":"Hemasphere"},{"issue":"1","key":"73325_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","volume":"11","author":"R Agius","year":"2020","unstructured":"Agius, R. et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat. Commun. 11 (1), 363 (2020).","journal-title":"Nat. Commun."},{"key":"73325_CR5","doi-asserted-by":"publisher","first-page":"674492","DOI":"10.3389\/fonc.2021.674492","volume":"11","author":"X Wu","year":"2021","unstructured":"Wu, X. et al. Altered T follicular helper cell subsets and function in chronic lymphocytic leukemia. Front. Oncol. 11, 674492 (2021).","journal-title":"Front. Oncol."},{"issue":"25","key":"73325_CR6","doi-asserted-by":"publisher","first-page":"eabo1782","DOI":"10.1126\/sciadv.abo1782","volume":"8","author":"PS Patel","year":"2022","unstructured":"Patel, P. S. et al. Translational regulation of TFH cell differentiation and autoimmune pathogenesis. Sci. Adv. 8 (25), eabo1782 (2022).","journal-title":"Sci. Adv."},{"issue":"1","key":"73325_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-022-00292-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie, Y., Yun, X., Zhang, Y. & Wang, X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp. Hematol. Oncol. 11 (1), 39 (2022).","journal-title":"Exp. Hematol. Oncol."},{"issue":"5","key":"73325_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41375-022-01519-y","volume":"36","author":"AM Vaca","year":"2022","unstructured":"Vaca, A. M. et al. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36 (5), 1324\u20131335 (2022).","journal-title":"Leukemia"},{"issue":"3","key":"73325_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/jleuko\/qiad006","volume":"113","author":"C Le Saos-Patrinos","year":"2023","unstructured":"Le Saos-Patrinos, C. et al. Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion. J. Leukoc. Biol. 113 (3), 305\u2013314 (2023).","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"73325_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/2326-6066.CIR-19-0748","volume":"8","author":"CH Koh","year":"2020","unstructured":"Koh, C. H. et al. GITR agonism triggers antitumor immune responses through IL21-Expressing follicular helper T cells. Cancer Immunol. Res. 8 (5), 698\u2013709 (2020).","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"73325_CR11","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2011.125","volume":"25","author":"T Herold","year":"2011","unstructured":"Herold, T. et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25 (10), 1639\u20131645 (2011).","journal-title":"Leukemia"},{"issue":"13","key":"73325_CR12","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2012-03-416461","volume":"120","author":"HY Chuang","year":"2012","unstructured":"Chuang, H. Y. et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 120 (13), 2639\u20132649 (2012).","journal-title":"Blood"},{"issue":"12","key":"73325_CR13","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/2159-8290.CD-21-0276","volume":"11","author":"L Penter","year":"2021","unstructured":"Penter, L. et al. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia Mirror Disease History. Cancer Discov. 11 (12), 3048\u20133063 (2021).","journal-title":"Cancer Discov."},{"issue":"5","key":"73325_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (5), 284\u2013287 (2012).","journal-title":"OMICS"},{"issue":"1","key":"73325_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat. Commun. 13 (1), 816 (2022).","journal-title":"Nat. Commun."},{"issue":"1","key":"73325_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell. Rep. 18 (1), 248\u2013262 (2017).","journal-title":"Cell. Rep."},{"issue":"12","key":"73325_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek, M. & Al-Sawaf, O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am. J. Hematol. 96 (12), 1679\u20131705 (2021).","journal-title":"Am. J. Hematol."},{"key":"73325_CR18","doi-asserted-by":"publisher","first-page":"985280","DOI":"10.3389\/fimmu.2022.985280","volume":"13","author":"T Liang","year":"2022","unstructured":"Liang, T. et al. Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia. Front. Immunol. 13, 985280 (2022).","journal-title":"Front. Immunol."},{"issue":"8","key":"73325_CR19","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","volume":"34","author":"PM Roessner","year":"2020","unstructured":"Roessner, P. M. & Seiffert, M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 34 (8), 2012\u20132024 (2020).","journal-title":"Leukemia"},{"issue":"9","key":"73325_CR20","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1182\/blood-2007-07-099531","volume":"111","author":"A Gowda","year":"2008","unstructured":"Gowda, A. et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111 (9), 4723\u20134730 (2008).","journal-title":"Blood"},{"issue":"20","key":"73325_CR21","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/bloodadvances.2021005883","volume":"6","author":"M Yano","year":"2022","unstructured":"Yano, M. et al. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 6 (20), 5641\u20135654 (2022).","journal-title":"Blood Adv."},{"issue":"3","key":"73325_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.12401","volume":"162","author":"MJ Ahearne","year":"2013","unstructured":"Ahearne, M. J. et al. Enhancement of CD154\/IL4 proliferation by the T follicular helper (tfh) cytokine, IL21 and increased numbers of circulating cells resembling tfh cells in chronic lymphocytic leukaemia. Br. J. Haematol. 162 (3), 360\u2013370 (2013).","journal-title":"Br. J. Haematol."},{"issue":"13","key":"73325_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2015-01-624585","volume":"126","author":"S Bhatt","year":"2015","unstructured":"Bhatt, S. et al. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood 126 (13), 1555\u20131564 (2015).","journal-title":"Blood"},{"issue":"5","key":"73325_CR24","doi-asserted-by":"publisher","first-page":"e22328","DOI":"10.1096\/fj.202200251R","volume":"36","author":"F Qian","year":"2022","unstructured":"Qian, F. et al. Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. FASEB J. 36 (5), e22328 (2022).","journal-title":"FASEB J."},{"key":"73325_CR25","doi-asserted-by":"crossref","unstructured":"Guarente, V. & Sportoletti, P. Lessons, challenges and Future Therapeutic opportunities for PI3K Inhibition in CLL. Cancers (Basel) 13 (6) (2021).","DOI":"10.3390\/cancers13061280"},{"issue":"10","key":"73325_CR26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-22-2386","volume":"29","author":"SS Chen","year":"2023","unstructured":"Chen, S. S. et al. Duvelisib eliminates CLL B cells, impairs CLL-Supporting cells, and overcomes Ibrutinib Resistance in a Xenograft Model. Clin. Cancer Res. 29 (10), 1984\u20131995 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"73325_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-023-01428-2","volume":"22","author":"A Barshidi","year":"2024","unstructured":"Barshidi, A. et al. The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. Cell. Commun. Signal. 22 (1), 59 (2024).","journal-title":"Cell. Commun. Signal."},{"key":"73325_CR28","doi-asserted-by":"crossref","unstructured":"Rubino, V. et al. Adaptive and innate cytotoxic effectors in chronic lymphocytic leukaemia (CLL) subjects with stable disease. Int. J. Mol. Sci. 24 (11) (2023).","DOI":"10.3390\/ijms24119596"},{"issue":"10","key":"73325_CR29","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41375-023-01984-z","volume":"37","author":"JG Fisher","year":"2023","unstructured":"Fisher, J. G. et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia 37 (10), 2036\u20132049 (2023).","journal-title":"Leukemia"},{"issue":"10","key":"73325_CR30","doi-asserted-by":"publisher","first-page":"e109533","DOI":"10.1371\/journal.pone.0109533","volume":"9","author":"N Ruiz-Lafuente","year":"2014","unstructured":"Ruiz-Lafuente, N. et al. The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFkappaB inhibitor. PLoS ONE 9 (10), e109533 (2014).","journal-title":"PLoS ONE"},{"key":"73325_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fimmu.2018.00227","volume":"9","author":"E Chiffoleau","year":"2018","unstructured":"Chiffoleau, E. C-Type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front. Immunol. 9, 227 (2018).","journal-title":"Front. Immunol."},{"issue":"1","key":"73325_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu, J., Sun, H., Cao, W., Song, Y. & Jiang, Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp. Hematol. Oncol. 11 (1), 3 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"73325_CR33","doi-asserted-by":"publisher","first-page":"669964","DOI":"10.3389\/fimmu.2021.669964","volume":"12","author":"Q Lemasson","year":"2021","unstructured":"Lemasson, Q., Akil, H., Feuillard, J. & Vincent-Fabert, C. Genetically Engineered Mouse models support a major role of Immune checkpoint-dependent immunosurveillance escape in B-Cell lymphomas. Front. Immunol. 12, 669964 (2021).","journal-title":"Front. Immunol."},{"key":"73325_CR34","doi-asserted-by":"publisher","first-page":"1077436","DOI":"10.3389\/fonc.2022.1077436","volume":"12","author":"ZH Wang","year":"2022","unstructured":"Wang, Z. H., Li, W., Dong, H. & Han, F. Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Front. Oncol. 12, 1077436 (2022).","journal-title":"Front. Oncol."},{"issue":"12","key":"73325_CR35","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1172\/JCI96610","volume":"128","author":"H Lewinsky","year":"2018","unstructured":"Lewinsky, H. et al. CD84 regulates PD-1\/PD-L1 expression and function in chronic lymphocytic leukemia. J. Clin. Invest. 128 (12), 5465\u20135478 (2018).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"73325_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1158\/2326-6066.CIR-20-1023","volume":"10","author":"M Klopotowska","year":"2022","unstructured":"Klopotowska, M. et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-Modified NK cells under oxidative stress. Cancer Immunol. Res. 10 (2), 228\u2013244 (2022).","journal-title":"Cancer Immunol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73325-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73325-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T09:05:18Z","timestamp":1727514318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73325-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["73325"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-73325-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"12 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (No. 20211015-47).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"22443"}}